Axsome Therapeutics Reports Strong Q3 2026 Results Driven by AUVELITY Growth
Axsome Therapeutics (AXSM) reported significant financial growth for the third quarter of 2026, with total revenue reaching $259.7 million, a 52% increase year-over-year. This surge was primarily driven by AUVELITY, which saw net product sales of $207.6 million due to high demand in major depressive disorder and Alzheimer’s disease agitation markets. Other products like SUNOSI and SYMBRAVO also showed robust double-digit growth. The company significantly narrowed its net loss to $12.9 million ($0.25 per share) compared to a much larger loss in the prior year, reflecting improved operational efficiency despite increased commercialization spending. With a cash position of $313.9 million, management expects to fund operations through to cash flow positivity. Looking ahead, investors are focused on upcoming PDUFA dates and Phase III clinical trial results expected throughout 2027.
Tickers: $AXSM
Topics: net loss improvement prescription volume product sales revenue growth